EP0690917A4 - Recombinant epstein-barr virus protein and its use in vaccine - Google Patents

Recombinant epstein-barr virus protein and its use in vaccine

Info

Publication number
EP0690917A4
EP0690917A4 EP94911554A EP94911554A EP0690917A4 EP 0690917 A4 EP0690917 A4 EP 0690917A4 EP 94911554 A EP94911554 A EP 94911554A EP 94911554 A EP94911554 A EP 94911554A EP 0690917 A4 EP0690917 A4 EP 0690917A4
Authority
EP
European Patent Office
Prior art keywords
vaccine
barr virus
virus protein
epstein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94911554A
Other languages
German (de)
French (fr)
Other versions
EP0690917A1 (en
Inventor
Ramesh Prakash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Laboratories UT Inc
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of EP0690917A1 publication Critical patent/EP0690917A1/en
Publication of EP0690917A4 publication Critical patent/EP0690917A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP94911554A 1993-03-12 1994-03-11 Recombinant epstein-barr virus protein and its use in vaccine Withdrawn EP0690917A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3118693A 1993-03-12 1993-03-12
US31186 1993-03-12
PCT/US1994/002637 WO1994020138A1 (en) 1993-03-12 1994-03-11 Recombinant epstein-barr virus protein and its use in vaccine

Publications (2)

Publication Number Publication Date
EP0690917A1 EP0690917A1 (en) 1996-01-10
EP0690917A4 true EP0690917A4 (en) 1996-05-22

Family

ID=21858082

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94911554A Withdrawn EP0690917A4 (en) 1993-03-12 1994-03-11 Recombinant epstein-barr virus protein and its use in vaccine

Country Status (6)

Country Link
EP (1) EP0690917A4 (en)
JP (1) JPH08507442A (en)
KR (1) KR960700749A (en)
AU (1) AU681131B2 (en)
CA (1) CA2156719A1 (en)
WO (1) WO1994020138A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858584B2 (en) 2000-05-02 2005-02-22 Theravance, Inc. Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
GB0210682D0 (en) 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173254A1 (en) * 1984-08-23 1986-03-05 Hans Joachim Wolf DNA sequences of the EBV genome, recombinant DNA molecules, processes for producing EBV-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173254A1 (en) * 1984-08-23 1986-03-05 Hans Joachim Wolf DNA sequences of the EBV genome, recombinant DNA molecules, processes for producing EBV-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. MICHA NUEBLING ET AL.: "Expression of Epstein-Barr virus membrane antigen gp350/220 in E. coli and in insects cells", VIROLOGY, vol. 191, no. 1, ORLANDO US, pages 443 - 447, XP023051347, DOI: doi:10.1016/0042-6822(92)90207-6 *
MANFRED MOTZ ET AL.: "Secretion of the two major Epstein-Barr virus glycoproteins (gp250/350) from recombinant chinese hamster ovary cells", VACCINES87. MODERN APPROACHES TO NEW VACCINES, pages 374 - 379 *
RALF JANKNECHT ET AL.: "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 88, WASHINGTON US, pages 8972 - 8976, XP002091128, DOI: doi:10.1073/pnas.88.20.8972 *
See also references of WO9420138A1 *

Also Published As

Publication number Publication date
AU681131B2 (en) 1997-08-21
WO1994020138A1 (en) 1994-09-15
CA2156719A1 (en) 1994-09-15
AU6404594A (en) 1994-09-26
JPH08507442A (en) 1996-08-13
KR960700749A (en) 1996-02-24
EP0690917A1 (en) 1996-01-10

Similar Documents

Publication Publication Date Title
ZA949104B (en) Recombinant viruses and their use in gene therapy
ZA951803B (en) Recombinant viruses their preparation and their therapeutic use
DE69526801D1 (en) AEROSOL FORMULATIONS WITH PEPTIDES AND PROTEINS
EP0704532A3 (en) Recombinant chimeric proteins and methods of use thereof
GB9320597D0 (en) Improvements in and realting to vaccines
ZA952563B (en) Recombinant viruses their preparation and their use in gene therapy
IL96647A0 (en) Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
ZA945012B (en) Viral vectors and their use in gene therapy
IL111682A0 (en) Recombinant viruses and their use in gene therapy
PL328791A1 (en) Vectors based on recombinational defective viral genomes and their application in vaccine folmulations
EP0445801A3 (en) Peptide and its use
EP0751955A4 (en) Super proteins including interferons and interleukins
EP0747482A3 (en) Hepatitis GB virus recombinant proteins and uses thereof
AU6299594A (en) Recombinant fowlpox virus s-fpv-043 and uses thereof
GB9516293D0 (en) Novel peptides and their use as vaccines
ZA9410217B (en) Recombinant human thymopoietin proteins and uses therefor.
ZA952242B (en) Recombinant viruses their preparation and their use in gene therapy
EP0690917A4 (en) Recombinant epstein-barr virus protein and its use in vaccine
GB2282601B (en) Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
EP0723584A4 (en) Recombinant infectious laryngotracheitis virus and uses thereof
EP0745133A4 (en) Recombinant infectious bovine rhinotracheitis virus s-ibr-052 and uses thereof
ZA952244B (en) Recombinant viruses their preparation and their use in gene therapy
AU2946395A (en) Recombinant infectious laryngotracheitis virus and vaccine
ZA952286B (en) Recombinant viruses their preparation and their use in gene therapy
ZA944725B (en) Recombinant antigens from mumps virus and their use in vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950907

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19960404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990810

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000406